OBJECTIVE: Systematic reviewers disagree about the ability of observational studies to answer questions about the benefits or intended effects of pharmacotherapeutic, device, or procedural interventions. This study provides a framework for decision making on the inclusion of observational studies to assess benefits and intended effects in comparative effectiveness reviews (CERs). STUDY DESIGN AND SETTING: The conceptual model and recommendations were developed using a consensus process by members of the methods workgroup of the Effective Health Care Program of the Agency for Healthcare Research and Quality. RESULTS: In considering whether to use observational studies in CERs for addressing beneficial effects, reviewers should answer two questions: (1) Are there gaps in the evidence from randomized controlled trials (RCTs)? (2) Will observational studies provide valid and useful information? The latter question involves the following: (a) refocusing the study questions on gaps in the evidence from RCTs, (b) assessing the risk of bias of the body of evidence of observational studies, and (c) assessing whether available observational studies address the gap review questions. CONCLUSIONS: Because it is unusual to find sufficient evidence from RCTs to answer all key questions concerning benefit or the balance of benefits and harms, comparative effectiveness reviewers should routinely assess the appropriateness of inclusion of observational studies for questions of benefit. Furthermore, reviewers should explicitly state the rationale for inclusion or exclusion of observational studies when conducting CERs.
OBJECTIVE: Systematic reviewers disagree about the ability of observational studies to answer questions about the benefits or intended effects of pharmacotherapeutic, device, or procedural interventions. This study provides a framework for decision making on the inclusion of observational studies to assess benefits and intended effects in comparative effectiveness reviews (CERs). STUDY DESIGN AND SETTING: The conceptual model and recommendations were developed using a consensus process by members of the methods workgroup of the Effective Health Care Program of the Agency for Healthcare Research and Quality. RESULTS: In considering whether to use observational studies in CERs for addressing beneficial effects, reviewers should answer two questions: (1) Are there gaps in the evidence from randomized controlled trials (RCTs)? (2) Will observational studies provide valid and useful information? The latter question involves the following: (a) refocusing the study questions on gaps in the evidence from RCTs, (b) assessing the risk of bias of the body of evidence of observational studies, and (c) assessing whether available observational studies address the gap review questions. CONCLUSIONS: Because it is unusual to find sufficient evidence from RCTs to answer all key questions concerning benefit or the balance of benefits and harms, comparative effectiveness reviewers should routinely assess the appropriateness of inclusion of observational studies for questions of benefit. Furthermore, reviewers should explicitly state the rationale for inclusion or exclusion of observational studies when conducting CERs.
Authors: Edward B Liebow; James H Derzon; John Fontanesi; Alessandra M Favoretto; Rich Ann Baetz; Colleen Shaw; Pamela Thompson; Diana Mass; Robert Christenson; Paul Epner; Susan R Snyder Journal: Clin Biochem Date: 2012-06-29 Impact factor: 3.281
Authors: Susan R Snyder; Alessandra M Favoretto; James H Derzon; Robert H Christenson; Stephen E Kahn; Colleen S Shaw; Rich Ann Baetz; Diana Mass; Corinne R Fantz; Stephen S Raab; Milenko J Tanasijevic; Edward B Liebow Journal: Clin Biochem Date: 2012-06-28 Impact factor: 3.281
Authors: Daniel A Barocas; Vivien Chen; Matthew Cooperberg; Michael Goodman; John J Graff; Sheldon Greenfield; Ann Hamilton; Karen Hoffman; Sherrie Kaplan; Tatsuki Koyama; Alicia Morgans; Lisa E Paddock; Sharon Phillips; Matthew J Resnick; Antoinette Stroup; Xiao-Cheng Wu; David F Penson Journal: J Comp Eff Res Date: 2013-07 Impact factor: 1.744
Authors: Marian S McDonagh; Daniel E Jonas; Gerald Gartlehner; Alison Little; Kim Peterson; Susan Carson; Mark Gibson; Mark Helfand Journal: BMC Med Res Methodol Date: 2012-09-12 Impact factor: 4.615